Global pharmaceutical manufacturer Lonza is expanding its production facilities in Pearland, Texas. Work began in March of 2016 on a 100,000-sf clinical manufacturing center, which will begin operations in late 2017. A second phase of construction will begin in fall of 2016 at the site, providing an additional 150,000 sf of office, laboratory, and manufacturing space.
Merck KGaA is planning to construct a $56 million pharmaceutical packaging plant on the campus of its headquarters in Darmstadt, Germany. Designed as a packaging center of excellence, the flexible 161,460-sf facility will optimize energy savings through the use of advanced production technologies. Completion is expected in late 2017 with full operations commencing in mid-2018. The project will be constructed to meet the most stringent international Good Manufacturing Practices (GMP) standards.
GE Healthcare is planning to create a $167 million biopharmaceutical manufacturing campus in Ringaskiddy, Ireland. Featuring GE's prefabricated KUBio™ facilities, GE BioPark Cork will include four KUBio factories owned by independent biopharma companies. GE will manage the campus as well as providing centralized shared utilities and site services. Construction is expected to begin in mid-2017.
The University of Hawaii broke ground in September of 2016 on the $33.6 million Daniel K. Inouye College of Pharmacy in Hilo. Designed by SmithGroupJJR and WCIT Architecture, the two-story, 45,000-sf instructional facility will provide teaching labs, lecture halls, simulation training suites, and administrative offices. Isemoto Contracting has been awarded the $31.3 million contract for the construction of the pharmacy school and occupancy is expected in late 2018.
GSK (GlaxoSmithKline) is investing £275 million to expand its pharmaceutical manufacturing capacity at three sites in the United Kingdom. A £92 million aseptic sterile facility will be built at Barnard Castle, and a £110 million plant for the production of respiratory active ingredients will be constructed at Montrose in Scotland. Lastly, GSK will spend £74 million to create additional manufacturing capacity for the Ellipta respiratory inhaler at its Ware campus. GSK's global headquarters are located in Brentford in the United Kingdom.
Agilent Technologies will begin construction in fall of 2016 on a 130,000-sf pharmaceutical manufacturing facility in Frederick, Colo. Doubling the life science company's commercial production capacity for oligonucleotides, the project will support the creation of therapies based on nucleic acid active pharmaceutical ingredients (APIs). Agilent is based in Santa Clara, Calif.
The University of Nebraska Medical Center celebrated the opening of the $35 million Center for Drug Discovery and Lozier Center for Pharmacy Sciences and Education in August of 2016 in Omaha. Designed by The Clark Enersen Partners and RDG, the three-story, 85,000-sf teaching and research facility provides advanced drug discovery labs, a sterile compounding suite, classrooms, faculty offices, auditoriums, simulation training suites, and a model pharmacy. Ground was broken on the project in June of 2013.
DYNALABS completed a 15,500-sf expansion of its pharmaceutical testing facility in St. Louis in July of 2016. The $1.5 million project added wet and dry labs, offices, conference rooms, a glass wash, sample management and inspection areas, and storage and distribution space. Designed and constructed by The Artisan Building Co., the facility was delivered for less than half of the original cost estimates from other contractors, enabling DYNALABS to invest in further capital improvements such as the planned renovation of an existing cleanroom.
AstraZeneca is building the £750 million Global R&D Centre and Corporate Headquarters on the Cambridge Biomedical Campus in the United Kingdom. Providing advanced facilities for pharmaceutical discovery and development, the 580,000-sf project will include space for biologics research, high throughput screening, medicinal chemistry, pre-clinical research, and clinical studies. Designed to optimize interaction and connectivity, the collaborative 11-acre campus will accommodate approximately 2,000 employees and will include an on-site energy center.
Pfizer broke ground in late June of 2016 on the $350 million Global Biotechnology Center in China. Located in the Hangzhou Economic Development Area (HEDA), the facility will manufacture pharmaceutical biosimilars, which are drugs designed with similar active properties to existing licensed therapies. The project will feature a modular production facility created by GE Healthcare that utilizes flexible, single-use biomanufacturing technologies. The duration of construction will be 18 months with completion expected in early 2018.
Pfizer broke ground in June of 2016 on a $200 million clinical manufacturing facility for complex biologics and vaccines in Andover, Mass. The five-story, 175,000-sf facility is expected to be fully operational by January of 2019 and will accommodate 75 employees. Designed for maximum flexibility, the project will feature five independent production suites that utilize next-generation manufacturing strategies including single-use bioreactors and disposable process technologies.
Pepperl+Fuchs began construction in June of 2016 on a 110,000-sf operations hub in Katy, Texas. Located in the West Ten Business Park, the $25 million project will act as the company’s regional headquarters and features an expanded engineering center, warehouse and distribution facilities, and a customer training area. Completion is expected in spring of 2017. Pepperl+Fuchs creates customized process automation solutions for the chemical, pharmaceutical, and manufacturing industries.
JHL Biotech opened a biopharmaceutical manufacturing facility in May of 2016 in Wuhan, China. Featuring single-use bioprocessing technologies, the cGMP facility utilizes GE Healthcare's prefabricated KUBio system to produce biosimilars and monoclonal antibodies for late–stage clinical trials and commercial supply. The project was completed in just 18 months.
Fujifilm Diosynth Biotechnologies opened a 62,000-sf biopharmaceutical manufacturing facility in May of 2016 in Morrisville, N.C. Accommodating collaborative research and development, the three-story BioProcess Innovation Center supports the creation and production of advanced proteins, vaccines, and monoclonal antibodies. The project team included Alexandria Real Estate Equities and KBR Building Group. Ground was broken on the project in January of 2015.
Valent BioSciences is planning to construct the Biorational Research Center at Innovation Park in Libertyville, Ill. Enabling the consolidation of the company's chemistry, biology, microbiology, fermentation, and formulations labs in a single location, the $22 million project includes the buildout of 65,000 sf to create labs and offices as well as the construction of a 10,000-sf research greenhouse. Completion is expected in mid-2017. Valent BioSciences is a subsidiary of Sumitomo Chemical Company.
